Top Markets
#1 Black Phoenix Black Phoenix +355.13%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.86%
#4 OpenEden OpenEden +60.23%
#5 Akedo Akedo +56.95%
#6 BasedHype BasedHype +26.68%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.51%
#9 Humanity Humanity +19.18%
#10 Ether.fi Ether.fi +17.32%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rangering i aksjer #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aksjekurs
$0.01292666
Sist synkronisert: 2025-04-08
Markedsverdi
$157.54K
Endring (1 dag)
6.84%
Endring (1 år)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Kategori

Healthcare
P/S-forhold for Synairgen plc (SNG)
P/S-forhold per August 2026 TTM: 0.00
Ifølge Synairgen plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0.00. Ved slutten av 2022 hadde selskapet et P/S-forhold på 0.00.
P/S-historikk for Synairgen plc fra 2004 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 86.19K 5,474.43%
2017 1.55K 0.00%
2016 0.00 -100.00%
2015 589.54K 12,229.42%
2014 4.78K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 68.65 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 134.85 -99.56%
2006 30.85K 158.87%
2005 11.92K 8,695.11%
2004 135.48 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE